Dr Massimo Cristofanilli, MD Joins Datar Cancer Genetics As Strategic Advisor

Dr. Cristofanilli has an esteemed career with over 400 scientific publications on cancer biomarkers, liquid biopsy, and targeted therapies. He is a past President of the International Society of Liquid Biopsy (ISLB).

"It is my pleasure to take up this role," said Dr. Cristofanilli. "I look forward to collaborating with the DCG team to drive the development of next-generation cancer diagnostic tests that will form the backbone of transformative technologies to detect and treat cancer."

Enhancing Cancer Diagnostics and Precision medicine

This collaboration will strengthen DCG's leadership in molecular and functional tumor profiling and liquid biopsies, particularly in circulating tumor cells (CTCs). Dr. Cristofanilli will work with DCG's research teams to expand biomarker-driven innovations for challenging cancers.

"Dr. Cristofanilli's expertise is invaluable to DCG's vision of pushing onco-diagnostics forward," said Dr. Darshana Patil, MD, Senior Director – Global Strategy and Medical Affairs, DCG. "His leadership will help refine strategies for next-generation, safer, and more reliable technologies," added Mr. Rajan Datar, Chairman and Managing Director, DCG.

About Datar Cancer Genetics

Datar Cancer Genetics is a global oncology research company developing non-invasive technologies for improved cancer detection, treatment, and management. The Company's state-of-the-art cancer research centres in the UK, and India are accredited by the relevant certification such as ISO, UKAS, ILAC, CAP and CLIA. The Company serves cancer patients and suspected cases in the UK, European Union, United States, GCC, and India.

About Dr. Massimo Cristofanilli

Dr. Cristofanilli is a board-certified medical oncologist specializing in molecular diagnostics, liquid biopsy, and drug development, with a focus on metastatic breast cancer. He is Director of Breast Medical Oncology and Scientific Director of the Englander Institute for Precision Medicine at Weill Cornell Medicine. A pioneer in Inflammatory Breast Cancer (IBC), he founded the IBC International Consortium and has co-authored over 400 peer-reviewed publications.

Photo:
Logo:

MENAFN11022025003732001241ID1109192203